CYDY News and Press, CytoDyn Inc From 03/12/21

CytoDyn recently reported Leronlimab's CD12 severe-to-critical data. The numbers were lackluster and failed to hit endpoints. Consequently, the bears have remerged and have triggered a substantial sell-off. After some analysis, the company revealed a subset of patients who benefited f...

I have seen some holdouts claiming CytoDyn might still use CD12 results to get some kind of approval. I show what's implied in CytoDyn's post hoc analysis, and it's not pretty. I also show why there's no doubt that no approval is coming from the CD12 trial, in CytoDyn's own words....

CytoDyn (CYDY) has enrolled and dosed 20 patients in the first 10 days of its Phase 2 trial for COVID-19 long-haulers symptoms. The trial is designed to enroll 50 patients.The trial will evaluate the efficacy and safety of leronlimab in patients with prolonged COVID-19 symptoms (lon...

VANCOUVER, Washington, March 11, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...

The CD12 trial on severe-to-critical COVID-19 failed. You wouldn't easily guess it from the 3 PRs CytoDyn issued on the subject. This article shows clearly why we know the trial failed, and why what CytoDyn did with the PRs is misleading and can't lead to leronlimab approval. ...

CytoDyn (CYDY) will release the CD12 clinical trial data via Form 8-K after the investment community webcast on Monday, March 8, 2021.The Company’s recently completed CD12 Phase 3 trial evaluated leronlimab in severe-to-critical COVID-19.Key findings are as follows:Survival benefit: Th...

These trial results are currently being prepared to be submitted for publication VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix...

CytoDyn (CYDY) announces multiple regulatory pathways for approval of leronlimab for critical COVID-19 in the U.S., U.K. and Canada. MHRA will accept more data from the open-label portion of Company's current CD12 trial. To date, an additional 46 patients have been enrolled, but the results h...

U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA CytoDyn submitted protocol to U.S. FDA for immediate enrollment of 140 critical COVID-19 patients with same sites as CD12 trial – enrollment to commence upon FDA commen...

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...